Abstract: The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.

Abstract: This invention relates to a dual phase mouthwash comprising a hydrophilic phase, a hydrophobic phase, and a hydrotrope, wherein the hydrophobic phase comprises coconut oil, as well as to methods of using and of making such compositions.

Abstract: A method of preparing a zinc citrate-containing oral care composition, the method comprising: (a) adding zinc oxide to a solution of citric acid in a solvent to form a suspension; (b) agitating the suspension until a clear solution is obtained; and (c) adding an additional oral care ingredient to the solution obtained in (b). Also, a method of preparing a zinc citrate-containing oral care composition, the method comprising: (a) adding citric acid to a suspension of zinc oxide in a solvent; (b) agitating the suspension until a clear solution is obtained; and (c) adding an additional oral care ingredient to the solution obtained in (b). In both methods, steps (a) and (b) are carried out at a temperature of from 10° C. to 50° C. and the molar ratio of zinc oxide to citric acid in step (a) is about 3:2.

Abstract: The present invention relates to a composition for dyeing keratin fibres, in particular keratin fibres such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof and/or solvates thereof such as hydrates; b) at least one coupler; c) at least one polymer chosen from cationic polymers and amphoteric polymers, and mixtures thereof; d) at least one fatty substance; the total amount of fatty substances being at least 10%, e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: The present invention relates to a composition for dyeing keratin fibres, in particular keratin fibres such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol acid salts thereof or solvates thereof such as hydrates; b) at least one heterocyclic oxidation base; c) at least one coupler; d) optionally at least one fatty substance; e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibres such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: The present invention describes a composition for colouring hair, comprising at least one dye having the formula (I) and at least one dye having the formula (II): where the groups are defined in the description. The composition provides hair colourings stable and brilliant at various pH values and also resistant to washing.

Abstract: The invention provides methods of hair loss or inducing new hair growth, as well as methods of preventing hair loss, comprising applying an effective amount of a dihydromyricetin compound to the scalp. The invention also provides methods of delaying or reversing signs of aging skin comprising applying an effective amount of a dihydromyricetin compound to the skin. Also provided are cosmetic products (e.g., skin and hair products) comprising a dihydromyricetin compound and methods of making the same.

Abstract: A cosmetic composition for dyeing keratinous fibers is provided herein. The cosmetic composition includes water and from about 6 to about 12 wt % organic solvent relative to the weight of the composition. The organic solvent includes from about 80 to about 100 wt % propylene carbonate and from about 0 to about 20 wt % benzyl alcohol. The cosmetic composition has a pH value in the range from about 1.0 to about 5.5 and at least one acid directly absorbed dye.

Abstract: The present invention relates to a process for dyeing keratin fibres, in particular human keratin fibres such as the hair, in which said fibres are treated using one or more cosmetic compositions comprising a) one or more dye(s), b) one or more titanium salts and optionally b1) at least one carboxylic acid, and c) one or more non-cellulosic-based polysaccharides, and d) optionally one or more chemical oxidizing agents such as hydrogen peroxide or one or more hydrogen peroxide-generating systems.

Abstract: An improved hair and scalp treatment composition comprising a hair care product wherein the improvement comprises reducing the comedogenicity thereof by excluding therefrom comedogenic elements having a Fulton scale grade greater than 2.

Abstract: Provided are compositions and methods that are useful for personal care compositions. The compositions comprise (a) a cationic polymer comprising polymerized units derived from (i) 30 to 80 weight % of cationic monomers, (ii) 10 to 65 weight % of (meth)acrylamide monomers, and (iii) 0 to 30 weight % of polar non-ionic derivatives of acrylic monomers, and (b) at least one cosmetically acceptable surfactant, rheology modifier, or cosmetic active. Also provided are methods of treating hair with such compositions.

Abstract: This invention relates to a composition, in the form of an oil-in-water emulsion, containing: at least one associative polyurethane complying with the formula (I), at least one nonionic surfactant, at least one fatty alcohol or one fatty acid comprising a fatty chain containing at least 20 carbon atoms, and at least one pigment, wherein the content of associative polyurethane active substance having formula (I) is strictly greater than 1.5% by weight in relation to the total weight of said composition.

Abstract: Inventive embodiments disclosed herein include an oil-in-water mascara formulation that includes non-emulsifying waxes in a concentration of 1 to 12 percent by weight; at least one viscosity modifier; and at least one non-wax grafted polymer and at least one wax grafted polymer with a combined concentration of 0.10 percent to 50 percent.

Abstract: The invention is directed to a composition comprising a first low-melt wax, a second low-melt wax, a high-melt wax, one or more oil phases, and optionally a flavoring agent.

Abstract: Compositions for tightening the skin and reducing muscle pain, bruising, and swelling in skin and methods of forming such compositions.

Abstract: Compositions for lubricating skin during application of a fascia tissue treatment device, thereby reducing the appearance of cellulite in skin and methods of forming such compositions.

Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanparticles, and polymeric microparticles or nanparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.

Abstract: The present invention is directed to a palatable soft chew veterinary composition comprising at least one active agent, at least one binding agent, at least one disintegrant, at least one wetting agent, and at least one flavorant, and methods for controlling or treating a condition in an animal comprising administering the composition to said animal in need thereof.

Abstract: Provided herein are edible compositions for reducing semen viscosity and/or enhancing semen flavor, and methods of using and preparing such compositions.

Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.

Abstract: The present invention relates to an oil-in-water nanoemulsion comprising an oil phase comprising at least one essential oil or water-immiscible phase comprising a hydrophobic polymer and/or a hydrophobic active dispersed in an aqueous phase, said nanoemulsion comprising nanometric droplets of said essential oil or said active with an interface consisting of amphiphilic derivatives of chitosan and at least one fatty acid, obtained by ionic interaction between the deacetylated amino groups of said chitosan and the carboxylic groups of said fatty acid.

Abstract: A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including: a) a container accommodating a pressurized product; and b) an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a nonsteroidal immunomodulating agent; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof; v. about 0.

Abstract: The present invention addresses the issue of providing an external composition for screen foamers such as pump foamers, that can be safely used even when not removed after application. Provided is an external composition for screen foamers, including a non-ionic surfactant as a foaming component and, ideally, being in a soluble state.

Abstract: Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.

Abstract: A method for stabilize reduced glutathione using micronized curcumin, to provide a solid and liquid composition or formulation comprising a dispersion of the micronized curcumin. Also, a method for improving the oxidative stability of a peptide in a composition by adding micronized curcumin with the composition, and dispersing the micronized curcumin into the composition containing the peptide. The composition can include a chewing gum.

Abstract: A composition for medical usage and method of preparing the same are provided. The composition comprises: at least one magnetic nanoparticle including a nanodiamond particle and at least one magnetic element, wherein the at least one magnetic element is embedded into the at least one nanodiamond particle by using an ion implantation system. The nanodimond particle can be synthesized with different components which can help medical effects of the composition.

Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Abstract: Pharmaceutical compositions are provided, which comprise effective amounts of an opioid analgesic such as oxycodone, and an antiemetic, such as promethazine, to treat a subject for conditions, including for reducing or eliminating an adverse effect associated with the opioid analgesic.

Abstract: Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.

Abstract: The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient.

Abstract: In one aspect the present invention features process for making a tablet comprising at least one pharmaceutically active agent, said method comprising the step of applying radiofrequency energy to a powder blend to sinter said powder blend into said tablet, wherein said powder blend comprises lossy coated particles and said at least one pharmaceutically active agent, wherein said lossy coated particles comprises a substrate that is at least partially coated with a lossy coating comprising at least one activator, wherein said substrate has a Q value of greater than 100 and said activator has a Q value of less than 75.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to the technical field of coating agent, in particular to a coating agent containing nano-SiO2 and a preparation method thereof. The coating agent consists of raw materials in parts by weight as follows: 50-60% film-forming agent, 5-10% plasticizing agent, 2-6% dispersing agent, 10-30% coloring agent, 15-20% antisticking agent and 2-5% nano-SiO2. In the present invention, the nano-SiO2. and the film-forming agent in the formulation can form a composite, which can enhance the property of coating agent, improve the coating film strength, and enhance the UV-protection and anti-discoloration functions, so as to improve the storage stability of drugs. The UV-protection and anti-discoloration functions of the coating agent prepared herein can be improved by more than 75%, and their film strength can be improved by more than 30%.

Abstract: The disclosure describes an injection molding process for coating a tablet core to produce a coated pharmaceutical tablet, wherein the injection-molded coating is substantially continuous (e.g., completely covers the tablet core with no openings), and describes the resulting coated pharmaceutical tablet. The disclosure describes compositions for coatings and tablet cores and equipment suitable for performing the process.

Abstract: The present invention relates to a microcontainer microstructure including a microcontainer film structure having a sharp tip portion and a method of manufacturing the same.

Abstract: Microparticles are prepared by a method that includes: (a) forming a layer comprising a first polymer on a solid surface by depositing a first composition one or more times on the solid surface, wherein the first composition comprises the first polymer and a first solvent, and evaporating the first solvent in the first composition; (b) forming one or more layers comprising a second polymer and a therapeutic agent by depositing a second composition on all or part of the layer formed in step (a), wherein the second composition comprises the second polymer, the therapeutic agent, and a second solvent; and evaporating the second solvent in the second composition; and (c) forming an additional layer comprising a third polymer by depositing a third composition one or more times on a previously formed layer, wherein the third composition comprises the third polymer and a third solvent; and evaporating the third solvent in the third composition.

Abstract: The present invention provides a process for forming a substance with a superstructure and a process for forming Janus particles. The novel application of the substance with the superstructure and the Janus particles are also disclosed in the present invention. The substance with the superstructure comprises vesicle and hydrogel. The vesicle and hydrogel are prepared in a solution with different ionic strength range.

Abstract: The invention relates to methods and materials for extending a circulating half-life of a protein. The method comprises conjugating a protein with a polymerizable acryloyl group and encapsulating the protein with a layer of poly(2-methacryloxyloxyethyl phosphorycholine) (pMPC). The layer of pMPC comprises a plurality of 2-methacryloxyloxyethyl phosphorycholine monomers (MPC) polymerized with a N,N?-methylenebisacrylamide (BIS) crosslinker.

Abstract: A particle comprising a first fraction containing an active ingredient and a second fraction containing a surfactant, and having a number average particle diameter of from 1 to 100 nm.

Abstract: The present invention provides a pharmaceutical preparation comprising a layer-by-layer thin film that is produced by alternately layering a polycation and a polyanion, and a drug loaded onto the layer-by-layer thin film. As a result, a pharmaceutical preparation with a prolonged duration of drug action with a single dose is provided.

Abstract: A system and method includes delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and the perfluorocarbon liquid comprises of an anti-inflammatory in a perfluorocarbon liquid and wherein the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

Abstract: A method for treating or preventing osteoporosis is provided that treats a patient with methylene blue.

Abstract: A formulation comprising an ophthalmically effective amount of one or more quinones of Formula I. Use of a formulation comprising one or more quinones of Formula I for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more quinones of Formula I is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more quinones of Formula I is also discussed.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The present invention relates to substituted Pyridyl-cycloalkyl-carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.

Abstract: A sulfonamide pharmaceutical composition. The present invention relates to a sulfonamide compound injectable preparation comprising a sulfonamide compound or a derivative thereof. The injectable preparation is prepared from the sulfonamide compound and a pharmaceutically acceptable carrier through certain preparation technologies. The sulfonamide compound injectable preparation involved in the present invention is stable and controllable in quality and effective.

Abstract: The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.

Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Abstract: A topical pharmaceutical or composition for prevention and treatment of irritation to skin cells. The composition comprises an aqueous solution of xylitol and glycerol. In a preferred embodiment, the composition comprises 5% (w/w) xylitol, 5% (w/w) glycerol, a viscosity-enhancing agent, base to bring to the pH to 4.9, and optionally, a pharmaceutically active agent.

Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.